Your Patients Need Darunavir — Here's How to Help Them Get It

When a patient tells you they can't fill their Darunavir prescription, the clock is ticking. Every day without antiretroviral therapy increases the risk of viral rebound and potential resistance development. As their prescriber, you're often in the best position to intervene quickly and effectively.

This guide provides a step-by-step approach to resolving Darunavir access issues — from identifying the root cause to connecting patients with the right resources.

Current Darunavir Availability

Darunavir is not in shortage as of 2026. Brand-name Prezista and multiple generic formulations (from Lupin, Mylan, Teva, Cipla, Aurobindo, and others) are actively manufactured and distributed across the United States.

The medications containing Darunavir include:

• Prezista (darunavir): 75 mg, 150 mg, 600 mg, 800 mg tablets; 100 mg/mL suspension
• Prezcobix (darunavir 800 mg + cobicistat 150 mg): tablet
• Symtuza (darunavir 800 mg + cobicistat 150 mg + emtricitabine 200 mg + TAF 10 mg): tablet
• Generic Darunavir: 400 mg, 600 mg, 800 mg tablets from multiple manufacturers

Why Patients Can't Find It

When patients report they can't get Darunavir, the issue typically falls into one of these categories:

Pharmacy Stocking

Most chain pharmacies maintain limited HIV medication inventory. Darunavir may not be on the shelf at a patient's preferred pharmacy, requiring a special order (24-48 hour turnaround). Specialty pharmacies and independent pharmacies serving HIV populations are far more likely to have continuous stock.

Insurance Barriers

Common insurance-related barriers include:

• Prior authorization: Required by many plans, particularly for brand-name products
• Step therapy: Some payers require trial of INSTI-based regimens before approving PI-based therapy
• Specialty tier placement: Brand-name Prezista, Prezcobix, and Symtuza are often on specialty tiers with high cost-sharing
• Non-formulary status: Rare, but some plans may not include specific formulations

Cost

Uninsured and underinsured patients face significant cost barriers:

• Brand Prezista: $1,300-$2,500/month
• Generic Darunavir: $400-$800 retail (as low as $60-$150 with discount coupons)
• Symtuza: $3,500-$4,500/month

What Providers Can Do: 5 Steps

Step 1: Identify the Barrier

Ask your patient (or their pharmacy) specifically what happened:

• Did the pharmacy say it's out of stock? → Stocking issue
• Did insurance deny the claim? → PA/formulary issue
• Is the patient unable to afford the copay? → Cost issue
• Is the patient having trouble finding any pharmacy with stock? → Distribution issue

The solution depends on the root cause. Don't assume — ask.

Step 2: Use Medfinder to Locate Stock

Medfinder for Providers allows you to check real-time pharmacy stock for Darunavir. You can search by medication and location to identify pharmacies near your patient that currently have the drug available.

This takes less than a minute and can be done during the visit. Send the patient home with a specific pharmacy name and phone number.

Step 3: Prescribe Generically When Possible

Writing for generic Darunavir (rather than Prezista) can:

• Reduce or eliminate prior authorization requirements
• Lower patient out-of-pocket costs significantly
• Improve pharmacy stock availability (generics are more widely distributed)

For adults on standard once-daily dosing, prescribe: Darunavir 800 mg once daily + Ritonavir 100 mg once daily. For treatment-experienced adults on twice-daily dosing: Darunavir 600 mg twice daily + Ritonavir 100 mg twice daily.

Note: The oral suspension (100 mg/mL) remains brand-only. Pediatric patients requiring weight-based liquid dosing will need brand-name Prezista suspension.

Step 4: Connect Patients with Financial Assistance

For patients facing cost barriers, initiate these referrals during the visit:

• ADAP enrollment: Contact your state's AIDS Drug Assistance Program. Covers Darunavir for income-qualifying patients in all 50 states.
• JJPAF (Johnson & Johnson Patient Assistance Foundation): Provides free Prezista for up to 1 year for uninsured/underinsured patients. Apply at prezista.com or call 1-800-652-6227.
• J&J withMe Savings Program: Reduces copay to $0 for commercially insured patients on brand-name Janssen HIV products.
• 340B pharmacy referral: If your clinic is a 340B covered entity, dispense or refer to a 340B pharmacy for reduced-price medications.
• Discount coupons: Direct patients to GoodRx or SingleCare for generic Darunavir pricing (as low as $60-$70/month).

For a patient-facing savings resource, direct patients to our Darunavir savings guide.

Step 5: Consider Therapeutic Alternatives If Needed

If Darunavir truly cannot be obtained in a timely manner, consider therapeutic alternatives based on resistance testing and treatment history:

• Atazanavir (Reyataz): Alternative boosted PI; once-daily dosing; generic available
• Lopinavir/Ritonavir (Kaletra): Alternative boosted PI; twice-daily; generic available; more GI side effects
• Dolutegravir (Tivicay): INSTI-based alternative; high barrier to resistance; once-daily; generic available in some markets
• Biktarvy: Complete INSTI-based STR; preferred first-line in current guidelines; brand-only

Always confirm the alternative is supported by the patient's resistance profile before switching. For more detail, see our alternatives to Darunavir overview.

Workflow Tips for Your Practice

Integrate these practices into your clinic workflow to reduce Darunavir access issues proactively:

• Confirm pharmacy stock before the patient leaves: Use Medfinder or call the pharmacy to verify Darunavir is available before sending the prescription
• Maintain a specialty pharmacy referral list: Keep updated contact information for 2-3 specialty pharmacies in your area that reliably stock HIV medications
• Submit prior authorizations proactively: If prescribing brand-name products, submit PA paperwork at the time of prescribing rather than waiting for a denial
• Bridge prescriptions when needed: Keep samples or have a process for providing a short bridge supply while pharmacy or insurance issues are resolved
• Schedule medication reviews: At each visit, ask patients if they've had any trouble getting their medications — don't wait for them to bring it up
• Assign a staff member to handle PA appeals: Designate someone in your practice to manage prior authorization requests and peer-to-peer reviews for HIV medications

Final Thoughts

Darunavir access challenges are solvable in nearly every case. The drug is available, the assistance programs exist, and tools like Medfinder for Providers make it easier than ever to connect patients with pharmacies that have stock.

The five-step approach — identify the barrier, locate stock, prescribe generically, connect with financial assistance, and consider alternatives — gives you a systematic way to resolve access issues quickly.

For additional context on the supply landscape, see our provider briefing on Darunavir availability in 2026. For patient-facing resources, direct patients to our guides on finding Darunavir in stock and saving money on Darunavir.